[Liver disease recurrence after liver transplantation]

Area of Science:

• Hepatology
• Transplantation Immunology
• Gastroenterology

Background:

• Liver transplantation is a standard treatment for end-stage liver disease.
• Graft dysfunction is often caused by the recurrence of the original liver disease.
• Autoimmune liver diseases recur in 15-30% of liver transplant recipients.

Purpose of the Study:

• To review the recurrence patterns of primary liver diseases after liver transplantation.
• To discuss the impact of immunosuppression on disease recurrence.
• To highlight challenges and successes in managing recurrent liver diseases post-transplant.

Main Methods:

• Literature review of studies on liver transplant outcomes.
• Analysis of recurrence rates for various liver diseases (autoimmune, viral, genetic).
• Evaluation of the role of immunosuppression and antiviral/immunoprophylaxis.

Main Results:

• Autoimmune liver diseases recur in 15-30% of cases, often with milder presentation due to immunosuppression.
• Hepatitis C recurrence leads to rapid cirrhosis; Hepatitis B recurrence is rare due to effective prophylaxis.
• Domino liver transplantation for familial amyloidotic polyneuropathy can lead to de novo amyloidosis in recipients.

Conclusions:

• Recurrence of the primary liver disease is a significant cause of long-term graft dysfunction.
• Immunosuppression modulates the clinical expression of recurrent autoimmune liver diseases.
• Effective immunoprophylaxis and antiviral therapies are crucial for preventing viral hepatitis recurrence, as seen with Hepatitis B.